Characterization and pharmacokinetics of a novel pirarubicin liposome powder

Drug Development and Industrial Pharmacy

Volumn 36, Issue 10, 2010, Pages 1186-1194

  Cong, Wenjuan ^a,b   Liu, Qingfei ^c   Chen, Xi ^b   Gao, Rong ^b   Lu, Juan ^b   Wang, Yiming ^b   Luo, Guoan ^a,b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b TSINGHUA UNIVERSITY   (China)

^c Tsinghua University   (China)

Author keywords

Cardiotoxicity; Characterization; Liposome powder; Pharmacokinetics; Pirarubicin

Indexed keywords

CHOLESTEROL; DISTEAROYLPHOSPHATIDIC ACID; DISTEAROYLPHOSPHATIDYLCHOLINE; LACTOSE; LIPOSOME; PIRARUBICIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TISSUE LEVEL; MOUSE; NONHUMAN; PARTICLE SIZE; POWDER;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG CARRIERS; DRUG STABILITY; EXCIPIENTS; LIPOSOMES; MALE; MICE; NEOPLASMS; PARTICLE SIZE; POWDERS; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 77956406102     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639041003695097     Document Type: Article

References (35)

1. Bangham AD, Standish MM, Watkins JC. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. JMol Biol, 13:238-52.
2. Maurer N, Fenske DB, Cullis PR. (2001). Developments in liposomal drug delivery systems. Expert Opin Biol Ther, 1:923-47.
3. Gary T, Jain S, Singh HP, Sharma A, Tiwary AK. (2008). Elastic liposomal formulation for sustained delivery of antimigraine drug: In vitro characterization and biological evaluation. Drug Dev Ind Pharm, 34:1100-10.
4. Zhao L, Wei YM, Zhong XD, Liang Y, Zhang XM, Li W, et al. (2009). PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. J Pharm Biomed Anal, 49:989-96.
5. Kawano K, Takayama K, Nagai T, Maitani Y. (2003). Preparation and pharmacokinetics of pirarubicin loaded dehydrationrehydration vesicles. Int J Pharm, 252:73-9.
6. Shi YY, Zhao HM, Wu CX. (1993). Relative binding free energy calculations of DNA to daunomycin and its 13-dihydro analogue. Int J Biol Macromol, 15:247-51.
7. Koh E, Ueda Y, Nakamura T, Kobayashi A, Takahashi H. (2002). Apoptosis in young rats with adriamycin-induced cardiomyopathy- comparison with pirarubicin, a new anthracycline derivative. Pediatr Res, 51:256-9.
8. Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, et al. (1995). Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in static breast cancer. Clin Cancer Res, 1:691-7.
9. Niitsu N, Yamazaki J, Nakayama M, Umeda M. (1998). Pirarubicin- induced myocardial damage in elderly patients with non- Hodgkins lymphoma. Nippon Ronen Igakkai Zashi, 35:358-62.
10. Mordente A, Meucci E, Silverstrini A, Martorana GE, Giardina B. (2009). New developments in anthracycline-induced cardiotoxicity. Curr Med Chem, 16:1656-72.
11. Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H, Sapir R. (2008). An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol, 61:695-702.
12. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, et al. (2007). Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta-Biomembr, 1768:678-87.
13. Dadashzadeh S, Vali AM, Rezaie M. (2008). The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Int J Pharm, 353:251-9.
14. Rezler EM, Khan DR, Fields JL, Cudic M, Lowell DB, Fields GB. (2007). Targeted drug delivery utilizing protein-like molecular architecture. J Am Chem Soc, 129:4961-72.
15. Chen J, Ping QN, Guo JX, Chu XZ, Song MM. (2006). Effect of phospholipids composition on characterization of liposomes containing 9-nitrocamptothecin. Drug Dev Ind Pharm, 32:719-26.
16. Zagana P, Haikou M, Giannopoulou E, Ioannou PV, Antimisiaris SG. (2009). Does the lipid membrane composition of arsonoliposomes affect their anticancer activity? A cell culture study. Mol Nutr Food Res, 53:592-9.
17. Kaplun YF, Touitou E. (1997). Testosterone skin permeation enhancement by menthol through formation of eutectic with drug and interaction with skin lipids. J Pharm Sci, 86:1394-9.
18. He J, Bernd T, Zang C, Zhang B, Zhu R, Wang F, et al. (2007). Unexpected effect of concomitantly administered curcumin on the pharmacokinetic of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol, 63:663-8.
19. Qin J, Chen DW, Lu WG, Xu H, Yan CY, Hu HY, et al. (2008). Preparation, characterization and evaluation of liposomal ferulic acid in vitro and in vivo. Drug Dev Ind Pharm, 34:602-8.
20. Dayan N, Touitou E. (2000). Carriers for skin delivery of trihexyphenidyl HCl: Ethosomes vs. liposomes. Biomaterials, 21:1879-85.
21. Chone S, Tauchi Y, Morimoto K. (2006). Influence of particle size on the distribution of liposomes to atherosclerotic lesions in mice. Drug Dev Ind Pharm, 32:125-35.
22. Medigene AG. (2008). Preparation unilamellar liposomes from suspension/solution in single-pass mode using high pressure homogenization for encapsulation of hydrophobic drugs e.g. paclitaxel, comprises extruding suspension/solution through porous device. EP 1920765-A1.
23. Taylor TM, Davidson PM, Bruce BD, Weiss J. (2005). Liposomal nanocapsules in food science and agriculture. Crit Rev Food Sci Nutr, 45:587-605.
24. Taylor TM, Gaysinsky S, Davidson PM, Bruce BD, Weiss J. (2007). Characterization of antimicrobial-bearing liposomes by z-potential, vesicle size and encapsulation efficiency. Food Biophys, 2:1-9.
25. Lo YL, Tsai JC, Kuo JH. (2004). Liposomes and disaccharides as carriers in spray-dried powder formulations of superoxide dismutase. J Control Release, 94:259-72.
26. Du S, Deng Y. (2006). Studies on the encapsulation of oxymatrine into liposomes by ethanol injection and pH gradient method. Drug Dev Ind Pharm, 32:791-7.
27. Jahn A, Vreeland WN, DeVoe DL, Locascio LE, Gaitan M. (2007). Microfludic directed formation of liposomes of controlled size. Langmuir, 23:6289-93.
28. Cong W, Liu Q, Liang Q,Wang Y, Luo G. (2009). Investigation on the interactions between pirarubicin and phospholipids. Biophys Chem, 143:154-60.
29. Tamilvanan S. (2004). Oil-in-water lipid emulsions: Implications for parenteral and ocular delivering systems. Prog Lipid Res, 43:489-533.
30. Pestana KC, Formariz TP, Franzini CM, Sarmento VHV, Chiavacci LA, Scarpa MV, et al. (2008). Oil-in-water lecithinbased microemulsions as a potential delivery system for amphotericin B. Colloids Surf B Biointerfaces, 66:253-9.
31. Iguchi H, Tone H, Ishikura T, Takeuchi T, Umezawa H. (1985). Pharmacokinetics and disposition of 4?-o-tetrahydropyranyladriamycin in mice by HPLC analysis. Cancer Chemother Pharmacol, 15:132-40.
32. Shimizu K, Qi XR, Maitani Y, Yoshii M, Kawano K, Takayama K, et al. (1998). Targeting of soybean-derived sterylglucoside liposomes to liver tumors in rat and mouse models. Biol Pharm Bull, 21:741-6.
33. Fujita H, Ogawa K, Tone H, Iguchi H, Shomura T, Murata S. (1986). Pharmacokinetics of doxorubicin, (2?R)-4?-o-tetrahydropyranyladriamycin and aclarubicin. J Antibiot, 39:1321-36.
34. Li X, Ding L, Xu Y, Wang Y, Ping Q. (2009). Targeted delivery of doxorubicin using stealth liposomes modified with transferring. Int J Pharm, 373:116-23.
35. Le UM, Shaker DS, Sloat BR, Cui ZR. (2008). A thermo-sensitive polymeric gel containing a gadolinium (Gd) compound encapsulated into liposomes significantly extended the retention of the Gd in tumors. Drug Dev Ind Pharm, 34:413-8.